Download PDF
Semin Thromb Hemost 2020; 46(07): 796-803
DOI: 10.1055/s-0040-1712157
Review Article

Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma

Paul F. Lindholm
1   Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
,
Glenn Ramsey
1   Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
,
Hau C. Kwaan
2   Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

In the ongoing pandemic of coronavirus disease 2019 (COVID-19), the novel virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is infecting a naïve population. The innate immunity of the infected patient is unable to mount an effective defense, resulting in a severe illness with substantial morbidity and mortality. As most treatment modalities including antivirals and anti-inflammatory agents are mostly ineffective, an immunological approach is needed. The mechanism of innate immunity to this viral illness is not fully understood. Passive immunity becomes an important avenue for the management of these patients. In this article, the immune responses of COVID-19 patients are reviewed. As SARS-CoV-2 has many characteristics in common with two other viruses, SARS-CoV that cause severe acute respiratory syndrome (SARS) and MERS-CoV (Middle East respiratory syndrome coronavirus) that causes Middle East respiratory syndrome (MERS), the experiences learned from the use of passive immunity in treatment can be applied to COVID-19. The immune response includes the appearance of immunoglobulin M followed by immunoglobulin G and neutralizing antibodies. Convalescent plasma obtained from patients recovered from the illness with high titers of neutralizing antibodies was successful in treating many COVID-19 patients. The factors that determine responses as compared with those seen in SARS and MERS are also reviewed. As there are no approved vaccines against all three viruses, it remains a challenge in the ongoing development for an effective vaccine for COVID-19.

Keywords

COVID-19 - MERS - SARS - immunity - immunoglobulin - convalescent plasma


Publication History

Article published online:
11 June 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Guan WJ, Liang WH, Zhao Y. et al; China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J 2020; 2000547
    CrossrefPubMedGoogle Scholar
  • 2 Guan WJ, Ni ZY, Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; (e-pub ahead of print) DOI: 10.1056/NEJMoa2002032.
    CrossrefPubMedGoogle Scholar
  • 3 Guo YR, Cao QD, Hong ZS. et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020; 7 (01) 11
    Google Scholar
  • 4 Zhou P, Yang XL, Wang XG. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579 (7798): 270-273
    Google Scholar
  • 5 Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018; 23 (02) 130-137
    CrossrefPubMedGoogle Scholar
  • 6 Lau YL, Peiris JS. Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol 2005; 17 (04) 404-410
    CrossrefPubMedGoogle Scholar
  • 7 Li G, Fan Y, Lai Y. et al. Coronavirus infections and immune responses. J Med Virol 2020; 92 (04) 424-432
    CrossrefPubMedGoogle Scholar
  • 8 Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): an updated overview for emergency clinicians. Emerg Med Pract 2020; 22 (05) 1-28
    Google Scholar
  • 9 Adhikari SP, Meng S, Wu YJ. et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020; 9 (01) 29
    CrossrefPubMedGoogle Scholar
  • 10 Chu CM, Cheng VC, Hung IF. et al; HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59 (03) 252-256
    CrossrefPubMedGoogle Scholar
  • 11 Arabi YM, Asiri AY, Assiri AM. et al; and the Saudi Critical Care Trials group. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials 2020; 21 (01) 8
    CrossrefPubMedGoogle Scholar
  • 12 Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020; 177: 104762
    CrossrefPubMedGoogle Scholar
  • 13 Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14 (01) 72-73
    CrossrefPubMedGoogle Scholar
  • 14 Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38 (01) 1-9
    PubMedGoogle Scholar
  • 15 Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol 2016; 38 (04) 471-482
    CrossrefPubMedGoogle Scholar
  • 16 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 17 Donnelly CA, Ghani AC, Leung GM. et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003; 361 (9371): 1761-1766
    CrossrefPubMedGoogle Scholar
  • 18 Leung TF, Wong GWK, Hon KLE, Fok TF. Severe acute respiratory syndrome (SARS) in children: epidemiology, presentation and management. Paediatr Respir Rev 2003; 4 (04) 334-339
    CrossrefPubMedGoogle Scholar
  • 19 Wong CK, Lam CW, Wu AK. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136 (01) 95-103
    CrossrefPubMedGoogle Scholar
  • 20 Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine 2018; 104: 8-13
    CrossrefPubMedGoogle Scholar
  • 21 Wu F, Zhao S, Yu B. et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579 (7798): 265-269
    CrossrefPubMedGoogle Scholar
  • 22 Channappanavar R, Fehr AR, Zheng J. et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest 2019; 130: 3625-3639
    CrossrefPubMedGoogle Scholar
  • 23 Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res 2014; 59 (1-3): 118-128
    CrossrefPubMedGoogle Scholar
  • 24 Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386 (9997): 995-1007
    CrossrefPubMedGoogle Scholar
  • 25 Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39 (05) 529-539
    Google Scholar
  • 26 Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 2005; 5 (12) 917-927
    CrossrefPubMedGoogle Scholar
  • 27 Kuchar E, Miśkiewicz K, Nitsch-Osuch A, Szenborn L. Pathophysiology of clinical symptoms in acute viral respiratory tract infections. Adv Exp Med Biol 2015; 857: 25-38
    CrossrefPubMedGoogle Scholar
  • 28 Murin CD, Wilson IA, Ward AB. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nat Microbiol 2019; 4 (05) 734-747
    CrossrefPubMedGoogle Scholar
  • 29 He W, Tan GS, Mullarkey CE. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. PNAS 2016; 113 (42) 11931-11936
    CrossrefPubMedGoogle Scholar
  • 30 Yang F, Xiao Y, Lu R. et al. Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus. Emerg Microbes Infect 2020; 9 (01) 664-675
    CrossrefPubMedGoogle Scholar
  • 31 Pelegrin M, Naranjo-Gomez M, Piechaczyk M. Antiviral monoclonal antibodies: can they be more than simple neutralizing agents?. Trends Microbiol 2015; 23 (10) 653-665
    CrossrefPubMedGoogle Scholar
  • 32 Kumar D, Romero Y, Schuck KN, Smalley H, Subedi B, Fleming SD. Drivers and regulators of humoral innate immune responses to infection and cancer. Mol Immunol 2020; 121: 99-110
    CrossrefPubMedGoogle Scholar
  • 33 Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. Ecancermedicalscience 2020; 14: 1023
    CrossrefPubMedGoogle Scholar
  • 34 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395 (10223): 473-475
    CrossrefPubMedGoogle Scholar
  • 35 Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395 (10225): 683-684
    CrossrefPubMedGoogle Scholar
  • 36 Zha L, Li S, Pan L. et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust 2020; (e-pub ahead of print) DOI: 10.5694/mja2.50577.
    CrossrefPubMedGoogle Scholar
  • 37 Liu WJ, Zhao M, Liu K. et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res 2017; 137: 82-92
    CrossrefPubMedGoogle Scholar
  • 38 Liu W, Fontanet A, Zhang PH. et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis 2006; 193 (06) 792-795
    CrossrefPubMedGoogle Scholar
  • 39 Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci 2020; 16 (10) 1718-1723
    CrossrefPubMedGoogle Scholar
  • 40 Lin Q, Zhu L, Ni Z, Meng H, You L. Duration of serum neutralizing antibodies for SARS-CoV-2: lessons from SARS-CoV infection. J Microbiol Immunol Infect 2020; (e-pub ahead of print) DOI: 10.1016/j.jmii.2020.03.015.
    CrossrefPubMedGoogle Scholar
  • 41 Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets 2017; 21 (02) 131-143
    CrossrefPubMedGoogle Scholar
  • 42 Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020; 38 (01) 10-18
    PubMedGoogle Scholar
  • 43 Tang XC, Marasco WA. Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy. Immunotherapy 2015; 7 (06) 591-594
    CrossrefPubMedGoogle Scholar
  • 44 Tang J, Zhang N, Tao X. et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother 2015; 11 (05) 1244-1250
    CrossrefPubMedGoogle Scholar
  • 45 Tian X, Li C, Huang A. et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020; 9 (01) 382-385
    CrossrefPubMedGoogle Scholar
  • 46 Hung IFN, To KKW, Lee C-K. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144 (02) 464-473
    CrossrefPubMedGoogle Scholar
  • 47 Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med 2020; 46 (02) 315-328
    CrossrefPubMedGoogle Scholar
  • 48 Bloch EM, Shoham S, Casadevall A. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 138745
    PubMedGoogle Scholar
  • 49 Payne S. ed. Methods to study viruses. In: Viruses from Understanding to Investigation. London: Academic Press; 2017: 37-52
    Google Scholar
  • 50 Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 2006; 145 (08) 599-609
    CrossrefPubMedGoogle Scholar
  • 51 O'Malley JJ, Hartman FW. Treatment of influenzal pneumonia with plasma of convalescent patients. J Am Med Assoc 1919; 72: 34
    CrossrefPubMedGoogle Scholar
  • 52 McGuire LW, Redden WR. Treatment of influenzal pneumonia by the use of convalescent human serum: Second report. J Am Med Assoc 1919; 72: 709
    CrossrefPubMedGoogle Scholar
  • 53 Sanborn G. The use of the serum of convalescents in the treatment of influenza pneumonia: a summary of the results in a series of one hundred and one cases. Boston Med Surg J 1920; 183: 171-177
    CrossrefPubMedGoogle Scholar
  • 54 Mair-Jenkins J, Saavedra-Campos M, Baillie JK. et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211 (01) 80-90
    CrossrefPubMedGoogle Scholar
  • 55 Hung IF, To KK, Lee C-K. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52 (04) 447-456
    CrossrefPubMedGoogle Scholar
  • 56 Beigel JH, Tebas P, Elie-Turenne M-C. et al; IRC002 Study Team. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 2017; 5 (06) 500-511
    CrossrefPubMedGoogle Scholar
  • 57 Beigel JH, Aga E, Elie-Turenne MC. et al; IRC005 Study Team. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med 2019; 7 (11) 941-950
    CrossrefPubMedGoogle Scholar
  • 58 Cheng Y, Wong R, Soo YO. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24 (01) 44-46
    CrossrefPubMedGoogle Scholar
  • 59 Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. Br J Haematol 2020; 189 (01) 39-53
    CrossrefPubMedGoogle Scholar
  • 60 Arabi Y, Balkhy H, Hajeer AH. et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 2015; 4: 709
    CrossrefPubMedGoogle Scholar
  • 61 Ko JH, Seok H, Cho SY. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 2018; 23 (07) 617-622
    CrossrefPubMedGoogle Scholar
  • 62 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; (e-pub ahead of print) DOI: 10.1073/pnas.2004168117.
    CrossrefPubMedGoogle Scholar
  • 63 Shen C, Wang Z, Zhao F. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; (e-pub ahead of print) DOI: 10.1001/jama.2020.4783.
    CrossrefPubMedGoogle Scholar
  • 64 Tiberghien P, de Lambalerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how. Vox Sang 2020; (e-pub ahead of print) DOI: 10.1111/vox.12926.
    CrossrefPubMedGoogle Scholar
  • 65 Zhang JS, Chen JT, Liu YX. et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol 2005; 77 (02) 147-150
    CrossrefPubMedGoogle Scholar
  • 66 Hung IF, To KK, Lee CK. et al. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. Clin Infect Dis 2010; 51 (03) 274-279
    CrossrefPubMedGoogle Scholar
  • 67 Ko JH, Müller MA, Seok H. et al. Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn Microbiol Infect Dis 2017; 89 (02) 106-111
    CrossrefPubMedGoogle Scholar
  • 68 Nurtop E, Villarroel PMS, Pastorino B. et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J 2018; 15 (01) 192
    CrossrefPubMedGoogle Scholar
  • 69 Nurtop E, Villarroel PMS, Pastorino B. et al. Correction to: Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J 2019; 16 (01) 12
    CrossrefPubMedGoogle Scholar
  • 70 Smatti MK, Al Thani AA, Yassine HM. Viral-induced enhanced disease illness. Front Microbiol 2018; 9: 2991
    CrossrefPubMedGoogle Scholar
  • 71 U.S. Food and Drug Administration. Investigational COVID-19 convalescent plasma: guidance for industry. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma . Accessed May 6, 2020
    Google Scholar
  • 72 Ahn DG, Shin HJ, Kim MH. et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol 2020; 30 (03) 313-324
    CrossrefPubMedGoogle Scholar
  • 73 He Y, Zhou Y, Liu S. et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004; 324 (02) 773-781
    CrossrefPubMedGoogle Scholar
  • 74 He Y, Zhou Y, Wu H. et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004; 173 (06) 4050-4057
    CrossrefPubMedGoogle Scholar
  • 75 Kim TW, Lee JH, Hung CF. et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 2004; 78 (09) 4638-4645
    CrossrefPubMedGoogle Scholar
  • 76 Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 2003; 16 (01) 69-86
    CrossrefPubMedGoogle Scholar
  • 77 Wang SF, Tseng SP, Yen CH. et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 2014; 451 (02) 208-214
    CrossrefPubMedGoogle Scholar
  • 78 Wan Y, Shang J, Sun S. et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020; 94 (05) 94
    CrossrefPubMedGoogle Scholar